PediCAP is a research project focused on antibiotic therapy of severe and very severe childhood community acquired pneumonia. Through a collaboration between African and European partners it aims to provide data on optimal duration and oral step-down therapy for paediatric community acquired pneumonia.
Community-acquired pneumonia is common and remains associated with substantial morbidity and mortality, especially in lower and middle-income countries. While standardising care is one important component in reducing mortality from severe pneumonia initially requiring hospitalisation, the antibiotics used are also clearly key. Optimising antibiotic treatment includes defining the right drug, right duration, right delivery and right dose. At present, strong data to support clinical decision-making for each of these factors in very severe/severe childhood pneumonia requiring inpatient care in lower and middle-income countries are lacking.
Goals of PediCAP
- Fill the knowledge gaps on antibiotic therapy of community-acquired pneumonia in pediatric age, in terms of optimal duration, oral step-down schedule evaluating effectiveness, safety and selection of antimicrobial resistance.
- Evaluate economic impact of antibiotic therapy in terms of cost-effectiveness.
- Implement the infrastructure that links study sites in order to share knowledge, develop study specific and general research skill straining programme and promote capacity development initiatives.
Objectives of PediCAP
- Optimize antibiotic treatment for childhood pneumonia in low middle-income countries by a randomised trial using an innovative duration- response design.
- Understand if the rate of clinical cure is superior with co-amoxiclav vs amoxicillin oral step-down therapy.
- Clarify the optimal antibiotic treatment duration that achieves high rates of clinical cure while minimising length of hospital stay, toxicity and antimicrobial resistance.
- Detect if optimal antibiotic therapy duration vary by key characteristics, such as age or severity, suggesting that antibiotic duration should be personalised to specific subgroups.